Which One among the Pt-Containing Anticancer Drugs More Easily Forms Monoadducts with G and A DNA Bases? A Comparative Study among Oxaliplatin, Nedaplatin, and Carboplatin
- 24 June 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 50 (15) , 6965-6971
Abstract
The platination processes of DNA bases with second- and third-generation Pt(II) anticancer drugs have been investigated using density functional theory (DFT) combined with the conductor-like dielectric continuum model (CPCM) approach, in order to describe their binding mechanisms and to obtain detailed data on the reaction energy profiles. Although there is no doubt that a Pt–N7 bond forms during initial attack, the energetic profiles for the formation of the monofunctional adducts are not known. Herein, a direct comparison between the rate of formation of the monofunctional adducts of the second- and third-generation anticancer drugs with guanine (G) and adenine (A) DNA bases has been made in order to spotlight possible common or different behavior. The guanine as target for platination process is confirmed to be preferred over adenine for all the investigated compounds and for both the hydrolyzed forms considered in our investigation. The preference for G purine base is dominated by electronic factors and promoted by a more favorable hydrogen-bonds pattern, confirming the important role played by H-bonds in determining both structural and kinetic control on the purine platination process.Keywords
This publication has 55 references indexed in Scilit:
- Theoretical analysis of trans-[PtCl2(NH3)(thiazole)] and trans-[PtCl2(thiazole)2] binding to biological targets — Factors influence binding kinetics and adduct stabilityCanadian Journal of Chemistry, 2010
- New insights into the biotransformation and pharmacokinetics of oxaliplatinJournal of Pharmaceutical Sciences, 2009
- Neutral and Acidic Hydrolysis Reactions of the Third Generation Anticancer Drug OxaliplatinThe Journal of Physical Chemistry B, 2008
- The Degradation Pathways in Chloride Medium of the Third Generation Anticancer Drug OxaliplatinThe Journal of Physical Chemistry B, 2008
- Influence of dT20 and [d(AT)10]2 on Cisplatin Hydrolysis Studied by Two‐Dimensional [1H,15N] HMQC NMR SpectroscopyChemistry – A European Journal, 2005
- Solution Structure of a DNA Duplex Containing acis-Diammineplatinum(II) 1,3-d(GTG) Intrastrand Cross-Link, a Major Adduct in Cells Treated with the Anticancer Drug CarboplatinBiochemistry, 1999
- DNA Adducts of cis-Diamminedichloroplatinum(II) and Its Trans Isomer Inhibit RNA Polymerase II Differentially in VivoBiochemistry, 1995
- Ototoxicity following therapy for testicular cancerEuropean Journal of Cancer, 1993
- Energy-adjustedab initio pseudopotentials for the second and third row transition elementsTheoretical Chemistry Accounts, 1990
- CarboplatinDrugs, 1989